At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,006 enrolled
Drug / intervention
Prevenar 13biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-interventional Study Of The Safety Of Pneumococcal 13-valent Conjugate Vaccine (Prevenar 13) In The Philippines: A Post Marketing Surveillance Study
In Brief
An observational study evaluating Prevenar 13 for Pneumococcal Disease. Completed, enrolled 3,006 participants across 119 sites.
Detailed Summary
Prevenar 13 is safe for administration to Filipinos.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesPhilippines
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartDec 2011
Primary CompletionMay 2014
TodayJul 2026
First PostedJul 18, 2011
Enrollment StartDec 1, 2011
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 15.0 years ago
Interventions
Prevenar 13biological
Prevenar 13 vaccine as prescribed by the physician based on approved product indication